IDWeek 2015: Adult Infectious Disease

Preventing - and Planning for - the Next Influenza Pandemic

By October 11, 2015

Influenza surveillance and response remains an ongoing, and changing, challenge-and pandemic preparedness goes well beyond stockpiling vaccines, noted speakers at IDWeek 2015's closing plenary session.

Increased Mortality With Tigecycline as Adjunct Tx for Severe CDAD

By October 11, 2015

Tigecycline used as adjunctive therapy for severe Clostridium difficile-associated diarrhea (CDAD) led to higher rates of colectomy and higher mortality, according to results of a multicenter study presented by Candace Marr, DO, from the Catholic Health System and The State University of New York at Buffalo, Buffalo, NY, at IDWeek 2015.

Fluoroquinolones Linked to More Than Tendon Ruptures

By October 11, 2015

Treatment with fluoroquinolones was definitely associated with subsequent tendon ruptures, and was found to be a possible contributor in aortic aneurysms, presented Nick Daneman, MD, MSc, from the University of Toronto, Ontario, Canada, at IDWeek 2015.

Linezolid, Vancomycin Compared for MRSA Pneumonia

By October 11, 2015

There was no statistically significant difference in clinical outcomes between patients with methicillin-resistant Staphylococcus aureus (MRSA) pneumonia who were treated with linezolid and those treated with vancomycin except mortality, reported ManShan Celica Tong, PharmD, MPH, from Medical University of South Carolina, Charleston, SC, at IDWeek 2015.

Ceftolozane/Tazobactam May Be New Tx Option for Complicated Pyelonephritis

By October 11, 2015

The combination of ceftolozane and tazobactam showed comparable outcomes to levofloxacin in the treatment of complicated pyelonephritis, according to results from the Phase 3 ASEPCT-cUTI trial presented at IDWeek 2015.

Dual Therapy Could Reduce SSI Incidence By 63%

By October 10, 2015

Dual therapy with vancomycin plus a beta-lactam antibiotic may reduce surgical site infections (SSI) by up to 63%, a study presented at IDWeek 2015 has found, with the strongest association seen in cardiac procedures.

Probiotic Intervention May Reduce CDI Rates in Antibiotic Recipients

By October 10, 2015

Administering a three-Lactobacillus spp. probiotic to patients undergoing antibiotic therapy might reduce the frequency of nosocomial Clostridium difficile infections (CDI), suggest findings from a single-institution study reported at IDWeek 2015.

Renal Status Not a Factor for Tedizolid, Linezolid Efficacy in ABSSSI

By October 10, 2015

Renal impairment does not appear to affect the safety or clinical efficacy of tedizolid compared to linezolid among adults treated for skin and skin structure infections (ABSSSI), according to a post-hoc analysis of data from two randomized, controlled phase 3 clinical trials, reported at IDWeek 2015.

Inappropriate Empirical Antimicrobial Tx May Lengthen Hospitalization

By October 10, 2015

Patients with good prognoses suffer longer hospitalizations when they receive inappropriate empirical antimicrobial therapy for E. coli and other gram-negative bloodstream infections, according to study findings reported at IDWeek 2015.

Are C. diff Cure Rates Better With High Dose Vancomycin?

By October 10, 2015

High-dose oral vancomycin does not improve clinical outcomes over 125mg low dose vancomycin therapy among adult patients with nosocomial Clostridium difficile infection (CDI), according to retrospective study findings reported at IDWeek 2015